CPI CPI Adverse Event Management & Reporting

Question 1

Which of the following meets the FDA definition of a Serious Adverse Event (SAE) in a clinical trial?

Accepted Answer

Hospitalization required due to a study-related complication

Answer

Mild nausea lasting less than 24 hours

Answer

A temporary decrease in blood pressure without clinical significance

Answer

A minor rash resolving with topical treatment

Question 2

Within what timeframe must an investigator report a fatal or life-threatening unexpected SAE to the FDA under 21 CFR 312.32?

Accepted Answer

Within 7 calendar days

Answer

Within 15 calendar days

Answer

Within 30 calendar days

Answer

Within 48 hours

Question 3

What does it mean for an adverse drug reaction to be 'unexpected' in a clinical trial context?

Accepted Answer

The nature, severity, or specificity is not consistent with what is described in the Investigator's Brochure

Answer

The event occurred at a higher frequency than anticipated

Answer

The event has never been reported in the medical literature

Answer

The investigator did not anticipate it based on the subject's medical history

Question 4

Which form is used to report post-market safety problems with FDA-regulated products to the FDA?

Accepted Answer

FDA MedWatch Form 3500

Answer

FDA Form 1572

Answer

FDA Form 483

Answer

IND Annual Report Form

Question 5

What is the key distinction between an 'adverse event' (AE) and an 'adverse drug reaction' (ADR)?

Accepted Answer

An AE is any untoward occurrence regardless of causality; an ADR implies a causal relationship to the study drug

Answer

An AE occurs only in the treatment group; an ADR can occur in placebo groups

Answer

An ADR must be serious; an AE can be of any severity

Answer

An AE requires FDA reporting; an ADR is reported only to the sponsor

Question 6

Who is primarily responsible for reporting SAEs to the clinical trial sponsor?

Accepted Answer

The principal investigator or sub-investigator at the site

Answer

The IRB chairperson

Answer

The FDA district office

Answer

The Data Safety Monitoring Board